In May 2025, President Trump issued an executive order regarding prescription drug pricing, directing the secretary of HHS to communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices for U.S. patients in line with comparably developed nations and to facilitate direct-to-consumer purchasing programs. The ultimate impact and implementation of this executive order is unknown.
